May 22, 2008 — VistaGen Therapeutics, Inc., a biotechnology company using leading-edge embryonic stem cell (ES Cell) technologies for predictive toxicology and drug discovery, announced that Sanwa Kagaku Kenkyusho Co. Ltd. (Sanwa), an international pharmaceutical company headquartered in Nagoya, Japan, has, pursuant to the terms of the parties’ joint research an development agreement, selected to license three customized ES Cell-based beta-islet differentiation assay systems developed under the agreement. Financial terms were not disclosed.Sanwa will use these customized ES Cell assays to identify and screen new diabetes drug candidates.
The assay systems were developed to expand the capabilities of VistaGen's ES Cell technologies to discover novel biologic products to treat diabetes and to accelerate Sanwa's internal discovery and screening programs for new small molecule drug candidates for Type 1 and Type 2 diabetes... [PDF] VistaGen Therapeutics' Press Release -
